Get the Stockscreener App
187.03
1.43%
-2.72
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $187.03, with a volume of 2.12M.
It is down -1.43% in the last 24 hours and down -3.99% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$189.75
Open:
$188.22
24h Volume:
2.12M
Relative Volume:
1.11
Market Cap:
$290.06B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
56.17
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+3.00%
1M Performance:
-3.99%
6M Performance:
+105.53%
1Y Performance:
+167.38%
1-Day Range:
$186.44
$189.08
1-Week Range:
$182.67
$191.50
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca Maintains FTSE Presence Through Oncology and Global Healthcare - Kalkine Media
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC - Pharmaceutical Technology
AstraZeneca stock (US6549022043): New drug and earnings updates keep investors focused - AD HOC NEWS
Why Are Rolls-Royce and AstraZeneca Trending - Kalkine Media
Why is AstraZeneca attracting healthcare discussion across the United Kingdom market? - Kalkine Media
AstraZeneca Expands Healthcare Presence Across FTSE 100 Pharmaceutical - Kalkine Media
AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins - Seeking Alpha
AstraZeneca plc stock (GB0009895292): FDA approvals and oncology pipeline keep investors watching - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): FDA decisions and oncology pipeline keep investors alert - AD HOC NEWS
AstraZeneca Plc (LSE:AZN) Share Price, History, & News - twelfthmagpie.com
AstraZeneca wins FDA AdCom backing for Truqap in prostate cancer - MSN
AstraZeneca PLC stock (US6549022043): insider sale and oncology spotlight draw investor attention - AD HOC NEWS
Insider Sell: Mani Sharma Sells Shares of AstraZeneca PLC - GuruFocus
XXI WEALTH, LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca (AZN) officer Sharma Mani sells 11,893 Ordinary Shares in open market - Stock Titan
FTSE 100 Closes Week Upbeat; AstraZeneca Sees Oncology Approval Progress - Yahoo Finance UK
EU regulator backs approval for AstraZeneca's experimental breast cancer pill - Reuters
AstraZeneca and Daiichi cancer drugs clear regulatory hurdles - London South East
AstraZeneca PLC stock (US6549022043): oncology growth and new approvals keep investors watching - AD HOC NEWS
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates - AstraZeneca
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours - AstraZeneca
CT UK Capital underperforms as underweight on AstraZeneca, Shell - marketscreener.com
AZN News | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell despite strong analyst consensus - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
AstraZeneca plc stock (GB0009895292): Deutsche Bank reiterates Sell rating as pipeline and US listin - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): analysts update views as pipeline news keeps investors alert - AD HOC NEWS
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca stock holds steady after net debt rises £2.5 billion following dividend payment - Traders Union
AZN Technical Analysis | Trend, Signals & Chart Patterns | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio - 富途牛牛
How VEPPANU Approval Frames Expectations For AstraZeneca’s Camizestrant In ESR1 Disease - Yahoo Finance
AstraZeneca plc stock (GB0009895292): Latest catalyst after recent company news - AD HOC NEWS
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
AstraZeneca PLC stock (US6549022043): US drug approvals keep Big Pharma name in focus - AD HOC NEWS
AZN Stock Price and Chart — LSE:AZN - TradingView
AstraZeneca’s Earnings Call Balances Growth and Risk - TipRanks
AstraZeneca plc stock (GB0009895292): oncology momentum and new data keep investors watching - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): US drug approvals keep pharma giant in focus - AD HOC NEWS
AstraZeneca stock (GB0009895292): lung cancer data and Q1 update keep focus on oncology pipeline - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): US drug approvals and oncology milestone keep pipeline in focu - AD HOC NEWS
FDA approves AstraZeneca’s new kind of hypertension drug - BioPharma Dive
Flat trading for AstraZeneca stock as GBX13,902 resistance keeps gains in check - Traders Union
AstraZeneca plc stock (GB0009895292): US drug approvals trigger milestone payment and fresh attentio - AD HOC NEWS
AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation - Yahoo Finance
AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology PortfoliosAstraZeneca (NYSE:AZN) - Benzinga
New hypertension option as Astrazeneca’s Baxfendy wins FDA nod - BioWorld News
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy - Yahoo! Finance Canada
AstraZeneca CEO Pascal Soriot receives vested share award under performance plan - Investing.com
AstraZeneca (AZN) CEO granted 18,359 shares as performance award vests - Stock Titan
AstraZeneca receives US approval for Baxfendy to treat hypertension By Investing.com - Investing.com Nigeria
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):